Table 3 Cox proportional hazards regression analysis for progression free survival on pemetrexed
From: Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants
Variables | Univariate | Multivariate | ||
|---|---|---|---|---|
HR (95 % CI) | P value | HR (95 % CI) | P value | |
EML4-ALK variant 1 | 0.262 (0.098–0.699) | 0.007 | 0.262 (0.098–0.699) | 0.007 |
EML4-ALK variant 2 | 2.364 (0.305–18.344) | 0.410 | ||
EML4-ALK variant 3a/b | 1.366 (0.443–4.214) | 0.587 | ||
Non-EML4 variant | 2.890 (1.191–7.013) | 0.019 | ||